Search This Blog

Thursday, July 2, 2026

Walz Pardons Convicted Child-Molester, Blocking Deportation

 A Minnesota pardon board that includes Gov Tim Walz among its three members has issued a full pardon to a convicted Laotian child-molester, torpedoing Homeland Security's effort to deport him. The 42-year-old convict, Tou Lue Vang, submitted a letter to the board saying he regretted what he did -- and just like that, his criminal record is now clean as a whistle via unanimous decision. 

“Governor Tim Walz's decision to pardon an illegal alien convicted child rapist so he can remain in our country is disgusting,” said DHS spokeswoman Lauren Bis. “These are the criminal illegal aliens he and his Minnesota sanctuary politicians are protecting. Tou Lue Vang lost his legal status following his conviction for repeatedly sexually assaulting a 10-year-old girl." 

Tou Lue Vang told the pardons board that he had regrets about abusing a 10-year-old girl multiple times (DHS photo)

In a storyline that has Democrats co-conspiring to infuse precious "diversity" into the American bloodstream over more than three decades, the Clinton administration granted Vang legal status after he entered the United States as a child in 1994. Now, 2024 Democratic vice presidential nominee Tim Walz has  helped guarantee that the convicted sex fiend will be safe from deportation. The two other members of the pardon board are Minnesota Attorney General Keith Ellison and chief Supreme Court justice, Natalie Hudson

Vang was convicted of sexually assaulting a girl who was just 10 years old when his perverted acts began. He repeated the offense with the same girl between 2002 and 2004, and pathetically tried to buy her silence with an offer of just $10 in hush money.  After his conviction, an immigration judge ordered his removal way back in 2006.  

When he was first interrogated by police, Vang tried to sweep away the gravity of his actions, telling them, "it is a cultural thing...to marry and have sex with girls as young as 12.” Apparently, Walz -- who's heralded as a reliable "ally" for the LGBTQ crowd and famously put tampons in school-kids' boys rooms -- thinks diversity in sexual morality is our strength too. Vang's pardon quest was bolstered by a supportive letter to the board from his victim, along with many letters of support from the "community."  

Minnesota Gov Tim Walz was part of a unanimous decision that will prevent a child-molester's deportation

Minnesota is on a roll when it comes to helping Laotian criminals stay in America. "In May, the state pardoned Jai Vang, a criminal illegal alien from Laos, whose criminal record includes convictions for robbery, robbery of a business with a gun, and driving under the influence of liquor," noted DHS in a statement. He was ordered to be removed from the United States -- you better sit down for this --  in May 1996. The Clinton administration sprung him loose. Between March 2025 and June 2026, Minnesota has received 67 pardon requests that cite immigration woes as a reason for seeking forgiveness. Across all decisions made this year, the Minnesota board has approved an overwhelming 94% of pardons requested. 

Of course, the Trump administration is in a glass house when it comes to throwing rocks about pardons. Among too many other examples, Trump has stirred the disgust of victims and law-and-order Republicans alike with pardons or commutations of: 

  • Joseph Schwartz, a nursing home operator in New York convicted of a $39 million tax fraud scheme
  • Eliyahu Weinstein, a real estate developer who'd been convicted of a real estate Ponzi scheme; after his 24-year sentence was commuted after only a few months, he immediately started orchestrating a scheme in which he defrauded people who thought they were investing in deals to get scarce medical supplies to war-torn Ukraine
  • Sholam Weiss, who was staring down an 845-year sentence for racketeering, wire fraud, money laundering, and transporting stolen goods, after defrauding an insurer and its elderly policyholders out of £91 million; he fled the US before he could be prosecuted and was convicted in absentia
https://www.zerohedge.com/political/minnesota-gov-walz-pardons-convicted-child-molester-blocking-deportation

FDA Staffers Oppose Proposed Clearance Of Peptides

 by Zachary Stieber via The Epoch Times,

Food and Drug Administration staffers said in newly released documents that they do not support letting compound pharmacies manufacture seven popular peptides.

FDA personnel said in documents posted online on June 29 that there are safety concerns with the peptides, including the possibility of triggering immune responses that could lead to "life-threatening and catastrophic reactions."

They do not favor classifying BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon, or Semax in a way that would let pharmacies use them in compounded medicines.

Peptides are short chains of amino acids that act as building blocks of proteins and perform essential biological functions in the body. If permitted, compounding pharmacies can manufacture them for personalized medications tailored to patients' unique needs.

They have become popular among some fitness influencers and have received endorsement from Health Secretary Robert F. Kennedy Jr.

Compounding refers to doctors and pharmacists creating customized medicine by combining, mixing, or altering ingredients.

The documents were posed ahead of a scheduled meeting of the FDA's Pharmacy Compounding Advisory Committee, which will consider whether to support or oppose loosening restrictions on the peptides.

The FDA in April said it would not take action against compounding pharmacies that use some of the peptides, and is now considering whether to add them to a list of approved substances.

The FDA could create some guard rails within which peptides could be prepared by legitimate pharmacies, according to Scott Brunner, CEO of Alliance for Pharmacy Compounding, a trade association for pharmacies.

"We would urge the agency to look at this not as an up or down vote, but to consider a middle path that does address a very real public health concern," Brunner said.

Ban

The FDA in 2023 labeled more than a dozen peptides, including BPC-157 and KPC, as substances banned for compounding.

Officials at the time said there was a lack of information on the peptides. The available data indicated "significant safety risks," they said.

Kennedy has said the ban was illegal. Such bans should only happen if there is a safety signal, he has said.

No such safety signal was identified.

Rep. Diana Harshbarger (R-Tenn.), a pharmacist, wrote to officials in 2025 in support of allowing the compounding of six peptides, including BPC-157.

New Members

The FDA appointed multiple new members to the compounding panel, including seven who have links to businesses or clinics involved in peptide therapies.

That includes Robert Harshbarger, a Tennessee senator, pharmacist, and son of Rep. Harshbarger.

"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members," a Department of Health and Human Services spokesperson said.

"Candidates that could not meet existing ethics requirements were removed from consideration."

https://www.zerohedge.com/medical/fda-staffers-oppose-proposed-clearance-peptides

'KFF: These Women Had Their Breasts Removed to Thwart Cancer. Then Came the Pain'

 Three weeks after Sophia Bassan's mastectomy, she felt a stabbing pain beneath her right armpit. In the following months, painful shocks radiated through her chest and back. Her body became so sensitive that at times she couldn't wear a shirt or lift a fork to her mouth.

Bassan slept sitting up because it hurt to lie down, and she would flinch at the slightest touch.

"I remember thinking I was losing my mind," said Bassan, 43. "One time I was in so much pain that I had to take off my top, and then my cat's tail brushed against my back. I screamed."

Mastectomies are lifesaving surgeries that remove a patient's breasts to treat breast cancer, which affects 1 in 8 American women over their lifetimes, according to the American Cancer Society. Some women also undergo mastectomies as a preventive measure after a genetic test shows they have an increased risk for breast cancer.

In the months following surgery, many women are afflicted by post-mastectomy pain syndrome, or PMPS, which spans from uncomfortable to disabling and can last years.

Yet PMPS is inconsistently diagnosed and treated, leaving women like Bassan in agony as they hunt for relief and struggle to find doctors who take their pain seriously, according to a KFF Health News review of peer-reviewed research studies and interviews with pain specialists, surgeons, patients, and patient advocates.

Another problem is that PMPS is poorly defined, which contributes to the wide range of estimates for how common it is, reaching as high as more than 50% of mastectomy patients, according to studies. Even the low-end estimates, around 10%, would amount to tens of thousands of women.

PMPS care could improve if lawmakers pass the Advancing Women's Health Coverage Act, which was introduced in October to ensure insurance coverage after breast cancer treatment, including preventive mastectomies. The bill, which does not mention PMPS by name, covers complications including chronic pain. More research would help, but pain research has long been fractured across several medical specialties and, more recently, has been undermined by the administration of President Donald Trump, who last year proposed deep cuts to research funding at the NIH. After Congress rejected those cuts earlier this year, the White House slowed the release of NIH grant money, hindering ongoing and future scientific research.

"I've known women who've had chronic pain -- itching, burning, stabbing pain -- for years after mastectomies," said Kathy Steligo, an author of multiple books on breast cancer who said she has spoken with hundreds of patients. "Of all the problems, that is probably the one least talked about by surgeons."

Four mastectomy patients interviewed by KFF Health News told similar stories. In separate interviews, patients said their presurgery consultations did not raise the possibility of post-mastectomy pain syndrome, although each said they had signed forms that may have disclosed the chance of this complication. All said that they felt blindsided by the chronic pain, and some said their doctors dismissed their symptoms.

"Women don't know about this, and when they have complications, the doctors act like it is so rare, like they're so baffled," Bassan said. "But this is statistically predictable."

Jennifer Drubin Clark, 42, struggled with pain after her mastectomy in 2018, and it worsened after reconstructive breast surgery in 2019.

But her surgeon seemed to focus only on the appearance of her breast implants, she said.

"I couldn't play the piano. I wanted to blow-dry my hair, but I couldn't hold my arm above my head for more than 2 seconds. I couldn't hold my kids," Clark said. "Everything made me cry."

Pain Often Dismissed

Breast cancer survival rates have steadily increased since the 1980s thanks to improved cancer screening, genetic testing, better treatments, and a rise in mastectomy surgeries.

Post-mastectomy pain syndrome is a consequence of that success, according to recent research papers from anesthesiologists at Baylor University in Texas and surgeons in Chicago and New York. Both papers called for an increased focus on PMPS so that breast cancer patients can not only live longer but live well.

"In the past, when concern was predominantly on patient survival, this pain was often considered acceptable," plastic surgeons Jonathan Bank, MD, and Maureen Beederman, MD, wrote in a 2021 paper, adding that mastectomies and other breast surgeries "should be considered truly successful only if patients are pain-free."

Treatment for post-mastectomy pain has a long way to go, said anesthesiologist Sean Mackey, MD, PhD, who leads the pain medicine division at Stanford University. Mackey said this "undertreated" condition has no consistent definition for diagnosis, no standardized screening, and no treatment approved by the FDA.

Even the name is a misnomer, Mackey said, since the same pain can arise among women who've had other procedures, including lumpectomies and lymph node surgeries.

"The condition was historically dismissed," Mackey said. "Basically women were told: 'You're lucky to be alive. Some pain is expected. Suck it up and deal with it.'"

"That attitude has been slow to change," he said.

Bank, a New York surgeon who founded a clinic focused on post-mastectomy pain, said the pain is believed to be triggered by nerves that are severed during surgery and then left that way.

The nerves can be sutured back together to minimize pain, Bank said, but most breast surgeons haven't been trained to do this. So it is not surprising, he said, that some patients say their surgeons were dismissive of their pain after mastectomies.

"When doctors don't have an answer or don't know the solution, the easiest thing to do is say there is no problem," Bank said.

PMPS has been documented among cancer patients since the 1970s. Although the condition does not have an official definition, many researchers describe it as frequent pain in the chest, shoulder, arm, or armpit lasting at least 3 months after surgery.

Mastectomies intended to prevent breast cancer have become more common among women with elevated risks, including genetic mutations and a family history of the disease.

Bassan's grandmother died of breast cancer when she was 40. After her father died of cancer in 2023, a genetic test showed that she was at risk. Grieving and afraid, Bassan sought a preventive mastectomy without hesitation, she said.

Bassan said she was also inspired by actor Angelina Jolie, who disclosed her own preventive mastectomy in a 2013 column in the New York Times. Her account had such a significant impact on rates of genetic testing and preventive mastectomies that medical researchers have studied what they call the "Angelina Jolie effect."

"I was really swayed by that," Bassan said. "She made it sound, in a way, quite effortless."

The aftermath of Bassan's surgery was far worse than she expected. Using a computer for hours triggered paralyzing pain, so she lost her job and has been out of work for more than a year. Prescription pills dulled the pain but left her in a fog, she said. Desperate, she consulted with multiple doctors until one suggested a nerve stimulation machine, which provided fleeting relief.

About 9 months after her mastectomy, a breast reconstruction surgery lessened Bassan's pain, although she said it still returns in occasional waves. Even though her surgeries were covered by insurance, Bassan estimated her pain has cost her more than $200,000 in lost wages and drained savings.

"I did not expect to pay this price to have this surgery," Bassan said. "I don't know if it was worth it."

Other women have no real choice.

No 'Gold Standard' Solution

Jeni Golomb, 48, was diagnosed with stage II cancer in both breasts in 2023 and had a double mastectomy as soon as she could.

Doctors made boilerplate disclosures of possible complications, Golomb said, but she never heard the words "post-mastectomy pain syndrome" until after she had it.

Golomb now manages her chronic pain by taking 1,500 mg a day of gabapentin, an anti-seizure drug that can also be used to treat nerve pain. Golomb said she expects to take the drug for years. If she misses a dose, her pain comes roaring back.

"It was the worst pain I ever felt," Golomb said. "I labored to 10 cm, unmedicated, with one of my children, and that was not as bad as this. It was excruciating."

Gabapentin has proved effective at helping some mastectomy patients with stubborn pain, while others have responded to electrodes implanted in their spinal column, according to the Baylor study, published in 2024.

But that study also said there is "no current gold standard" for how to treat post-mastectomy pain and a scarcity of high-level evidence for what treatments are effective.

Baylor anesthesiologist Krishna Shah, MD, who co-authored the report, said many patients eventually find a helpful treatment, but it often takes "a bit of trial and error" to identify what works for each.

And sometimes they never find it.

Susan Dishell, 67, said that after her 2017 mastectomy for breast cancer and reconstruction surgery, she struggled for 5 years with pain in both shoulders, plus a burning sensation that her medical records identified as nerve pain.

Another surgery swapped out her breast implants to erase her shoulder pain in 2022, Dishell said, but doctors warned her then that her other pain was unlikely to improve.

Since then, she has tried prescription drugs, steroid injections, CBD oil, acupuncture, physical therapy, and chiropractor treatments.

None of it worked, she said, so she stopped trying.

"I have not slept through the night since I've had this," Dishell said. "But it's OK. It's not the most terrible price to pay to not have breast cancer."

https://www.medpagetoday.com/hematologyoncology/breastcancer/120658

New Evidence Links Progestogen Contraceptives to Brain Cancer Risk

 

  • Women using progestogen contraceptives had a significantly increased risk of meningioma, the most common type of brain cancer.
  • Consistent with other recent studies, injectable medroxyprogesterone was associated with the highest risk.
  • The study extended the association to oral contraceptives and IUDs.

Women who used progestogen contraceptives had a significantly increased risk of meningioma, including oral and injectable progestogen formulations and intrauterine devices (IUDs), a large Danish study showed.

Eight of the 12 progestogen formulations included in the analysis had statistically significant associations with meningioma. Among the eight contraceptive formulations, odds ratios for meningioma versus non-users of progestogens ranged from 40% higher for levonorgestrel to more than four times higher for injectable medroxyprogesterone. Progestogen use within the past year was associated with the highest meningioma risk.

The excess meningioma risk disappeared 5 years after discontinuation of a progestogen contraceptive, reported Charlotte Wessel Skovlund, PhD, of the Danish Medicines Agency in Copenhagen, and colleagues in JAMA Network Open.

"The numbers needed to harm differed greatly depending on the specific progestogen used and the age group, with the highest risk observed for the oldest women," the authors stated. "Medroxyprogesterone showed the highest risk with relatively low numbers needed to harm, whereas all combined oral contraceptives, oral progestogen-only contraceptives, and IUDs had relatively high numbers needed to harm, especially among the youngest women. However, the present study suggests an increased risk of meningioma for several progestogens not previously associated with meningioma."

The study adds to and extends a large volume of evidence linking progestogens to meningioma. Over the past 5 years, multiple studies have shown significant associations between the contraceptives and the most common type of brain cancer, particularly injectable medroxyprogesterone.

  • A French study involving 18,000 women undergoing intracranial surgery showed a 19-fold greater risk of meningioma among users of cyproterone acetate, which is not available in the U.S. An earlier study from France involving 250,000 women showed a sixfold greater risk of meningioma associated with the contraceptive.
  • A U.S.-based study involving almost 90,000 women showed a meningioma relative risk of 2.43 with depot medroxyprogesterone versus non-users. The risk increased modestly to 1.18 among users of oral medroxyprogesterone acetate.
  • Earlier this year, Swedish investigators reported a 76% higher odds for meningioma among users of hormonal contraceptives in general, driven by a fivefold increase with depot medroxyprogesterone. The odds declined to 1.34 for other progesterone contraceptives.

Late last year, the FDA approved a label change for depot medroxyprogesterone, adding a warning about meningioma risk. Additionally, the American College of Obstetricians and Gynecologists has published patient education and counseling information about the link between progestogen contraceptives and meningioma and advised its members to engage in shared decision-making discussions about contraceptive choices. The European Medicines Agency has assessed meningioma risk for various progestogen contraceptives and approved updated product information for cyproterone, nomegestrol, chlormadinone, and medroxyprogesterone, Skovlund and colleagues stated.

Evidence supporting the biological plausibility of the association comes from observation of progesterone receptors in up to 87% of all meningiomas. Multiple observational studies have described tumor growth during pregnancy in association with exogenous progesterone, followed by tumor regression after delivery or withdrawal of the hormonal treatment, the authors noted.

The Danish researchers continued the investigation with a case-control study covering the years 2000 to 2024. Using data from Danish national registries, they identified women with meningioma diagnoses and matched each case with 10 control patients without meningioma. Investigators then compared contraceptive use between the cases and control group. Data analysis included 1,473 women with meningioma and a control group of 14,717 women without meningioma.

The results showed a consistent pattern of increased risk of meningioma associated with use of progestogen contraceptives. Statistically significant odds ratios for meningioma emerged for:

  • Injectable medroxyprogesterone: OR 4.55 (95% CI 2.19-9.45)
  • Oral desogestrel: OR 1.73 (95% CI 1.17-2.56)
  • Desogestrel-ethinyl estradiol: OR 1.66 (95% CI 1.31-2.10)
  • Cyproterone: OR 1.61 (95% CI 1.00-2.59)
  • Drospirenone: OR 1.58 (95% CI 1.05-2.37)
  • High-dose levonorgestrel IUD: OR 1.58 (95% CI 1.28-1.94)
  • Gestodene: OR 1.44 (95% CI 1.17-1.77)
  • Levonorgestrel: OR 1.40 (95% CI 1.12-1.76)

The analysis yielded nonsignificant associations for norethisterone combination (OR 1.38, 95% CI 0.77-2.47), low-dose levonorgestrel IUD (OR 1.14, 95% CI 0.59-2.22), norgestimate (OR 1.04, 95% CI 0.70-1.54), and norethisterone (OR 0.95, 95% CI 0.57-1.57).

Disclosures

7 FDA decisions to watch for in Q3

 

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright rejected, including one for an mRNA vaccine that became the center of controversy earlier this year.

The third quarter of 2026 is looking like a busy one for the FDA, with seven noteworthy decisions on its docket, including one that could mark a first in Alzheimer’s disease care and another that could justify a recent high-value buyout.

Read below for more.

Vera aims to challenge big names in IgAN arena

In one of Q3’s earliest decisions, Vera Therapeutics is looking to join the IgA nephropathy game with its investigational fusion protein atacicept. The drug is currently under FDA review with a target action date of July 7.

Backing atacicept’s application are data from the Phase 3 ORIGIN 3 study, in which the drug elicited a 46% decrease in proteinuria at 36 weeks versus baseline, according to a November 2025 press release. Atacicept also eliminated blood in the urine in 81% of patients.

These data paint a “compelling profile” for atacicept, Guggenheim Partners said in a Nov. 6 note to investors, strengthened even further by the drug’s “excellent safety profile that is comparable to placebo.”

If approved, atacicept would compete with Otsuka Pharmaceuticals’ APRIL inhibitor Voyxact, which won the FDA’s greenlight in November last year, and Novartis’ complement inhibitor Fabhalta. Vertex Pharmaceuticals, meanwhile, is close on Vera’s heels with its own fusion protein povetacicept, which has an FDA action date of Nov. 30.

Moderna’s mRNA flu shot nears D-day after sparking controversy

Moderna’s investigational flu vaccine made headlines in February when the FDA hit the company’s application with a refusal-to-file letter, declining even to give the submission the time of day. The agency at the time said that Moderna’s study used a comparator group that “does not reflect the best-available standard of care.”

A few days later, after strong blowback and a hastily arranged type A meeting with the biotech, the FDA reversed course and accepted an adjusted application for review. This time, Moderna is seeking full approval of its mRNA vaccine, dubbed mRNA-1010, in adults 50 to 64 years, and accelerated approval in people 65 and older. A decision is expected on or before Aug. 5.

Moderna is supporting the vaccine with many late-stage studies establishing its efficacy. One readout in June 2025 showed the mRNA shot was 26.6% more effective than a licensed comparator flu vaccine in adults 50 years and up.

Last month, the FDA’s Vaccines and Related Biological Products Advisory Committee unanimously recommended the mRNA flu shot’s full approval for adults aged 50 through 64, and accelerated approval for those 65 and up.

Capricor hopes for cell therapy comeback in Duchenne

By Aug. 22, the FDA is expected to release its decision on deramiocel, Capricor Therapeutics’ investigational cell therapy for Duchenne muscular dystrophy.

An approval here would serve as a vindication for deramiocel, which was initially rejected by the FDA last summer. At the time, the regulator said Capricor’s data package for the product failed to satisfy the “statutory requirement for substantial evidence of effectiveness.”

After deramiocel aced a Phase 3 trial, the FDA lifted its complete response letter in March, allowing the application to once again move forward. Capricor is seeking full approval of the candidate.

Deramiocel uses a rare subset of allogeneic cells drawn from the heart that can modulate the immune response and reduce fibrosis. The treatment works by helping maintain the function of cardiac and skeletal muscles. Data from the Phase 2 HOPE-2 study, which supported deramiocel’s initial application, demonstrated significant improvements in upper-limb performance and cardiac function over placebo.

Capricor’s resubmission now also includes data from the Phase 3 HOPE-3 study, which in December hit both its primary and secondary endpoints, showing statistically significant benefits in upper-limb function and a slowed decline in cardiac function as measured by left ventricular ejection fraction. Deramiocel also slowed disease progression and boosted overall functional performance, according to further data revealed in March.

Ultragenyx times two: Pair of gene therapies up for approval

Q3 is shaping up to be crucial for Ultragenyx, with two gene therapies lined up for FDA verdicts: DTX401 for glycogen storage disease type 1a (GSD1a), set for Aug. 23, and UX111 for Sanfilippo syndrome type A, due Sept. 19.

The upcoming decision date is especially pressing for UX111, which has already been rejected once. The FDA declined to approve the gene therapy in July 2025, citing manufacturing issues. Ultragenyx emphasized at the time that the denial was due to reasons “not directly related to the quality of the product.”

UX111 uses an adeno-associated virus (AAV) vector to deliver a functioning copy of the SGSH gene, which in patients with Sanfilippo syndrome type A is mutated, giving rise to a broad array of neurological and developmental symptoms. Around 1 in every 50,000 to 250,000 people globally have one of the four types of Sanfilippo syndrome, with A being the most common.

Meanwhile, GSD1a is caused by pathogenic mutations to the G6PC gene, produces an enzyme, G6Pase, that plays a role in the release of glucose from its stores. A deficiency in this activity can lead to severe hypoglycemia in between meals, as well as other complications that make the condition life-threatening. Patients with GSD1a are treated with cornstarch, which serves as an exogenous source of glucose.

DTX401 works by stabilizing the expression and activity of G6Pase. In Phase 3 development, the gene therapy led to a “significant and clinically meaningful” decrease in patients’ need for daily cornstarch intake, while also minimizing hypoglycemia episodes, according a company news release in February.

Biogen, Eisai ride out 3-month delay for starter dose of Leqembi Iqlik

After extending its review for 3 months, the FDA set a decision date of Aug. 24 for Eisai and Biogen’s application for the use of an under-the-skin formulation of their Alzheimer’s disease therapy Leqembi to initiate patients onto the treatment.

The FDA has already signed off on a subcutaneous version of Leqembi, now marketed as Leqembi Iqlik. However, the September 2025 approval only allows the use of the injection for maintenance treatment—that is, patients should first have completed 18 months of intravenous Leqembi.

A nod for Leqembi Iqlik in the induction setting would make it the first anti-amyloid therapy for at-home dosing throughout the entire treatment journey, the companies said in a January news release.

At the J.P. Morgan Healthcare Conference that same month, CEO Chris Viehbacher acknowledged that a nod is “going to be extremely important” and would help Leqembi compete with Eli Lilly’s Kisunla, which is infused monthly, versus Leqembi’s biweekly schedule. Kisunla’s current convenience edge “is going to go away once we have a subcutaneous formulation,” Viehbacher said.

Nuvalent nears NSCLC ruling for drug that attracted GSK buyout

Fresh off its $10.6 billion acquisition agreement with GSK, Nuvalent is nearing a potential approval for its ROS1 inhibitor zidesamtinib for the treatment of non-small cell lung cancer (NSCLC). The FDA’s verdict is expected on or before Sept. 18.

Nuvalent is backing its application with data from the Phase 1/2 ARROS-1 study. A readout in September 2025 showed that zidesamtinib elicited a 44% objective response rate in patients who had undergone prior treatment with a tyrosine kinase inhibitor. This figure improved to 51% when focusing on those who had only one previous line of treatment.

Zidesamtinib was one of the two stars of last month’s GSK takeover, alongside the ALK blocker neladalkib, also being proposed for NSCLC. The pharma believes both molecules have “multi-blockbuster potential,” according to GSK’s June 9 announcement. Truist Securities in a note the same day projected combined peak revenues for the two drugs to hit $3.5 billion.

Scholar Rock gives muscle atrophy drug another try

Capping off this list is Scholar Rock’s myostatin blocker apitegromab, which the biotech is proposing for the treatment of spinal muscular atrophy. The FDA’s target action date is September 30.

Apitegromab is a monoclonal antibody that inhibits the activation of myostatin, a protein that works to negatively regulate the growth of muscles. By blocking myostatin, apitegromab improves muscle mass and strength, as well as overall patient function and quality of life, according to Scholar Rock’s website.

Scholar Rock bore this out in the Phase 3 SAPPHIRE study, which in October 2024 showed significant motor improvements in patients treated with the antibody versus placebo.

In September 2025, however, the FDA handed Scholar Rock a rejection, flagging violations at a Novo Nordisk–owned manufacturing site where apitegromab was supposed to be produced. Other applications have also been tripped up by this particular plant, including Regeneron’s high-dose Eylea.

In March, Scholar Rock refiled its package for apitegromab, noting that while it will continue to engage the Novo facility, the biotech will also enlist a second fill-finish facility in the U.S. to “strengthen the apitegromab supply chain.”

https://www.biospace.com/fda/7-fda-decisions-to-watch-for-in-q3